Abbott Laboratories (ABT) — Institutional Investor Activity (Q2 2026)

ABT ranks #56 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

2982 institutions disclose a position in ABT, but none treat it as a major bet — even Flossbach Von Storch Se, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

Charles Schwab Investment Management Inc has added to its ABT position for two straight quarters, increasing it by $3.8B to reach $5.4B today.

Capital International Investors has trimmed its ABT position for two straight quarters, cutting it by $4.8B while still holding $3.1B.

ABT is up 1.4% today, and institutions have been net buyers of $25.8B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ABT posted net income of $6.3B over the trailing twelve months, and currently trades at a P/E of 30.8.

• Profitable — net income of $6.3B over the trailing twelve months
• Revenue grew 6.6% year over year
• Net income declined year over year, from $13.5B to $6.3B
• Generated $9.6B in positive operating cash flow
• Current ratio of 1.58x — enough short-term assets to cover short-term liabilities